P0293 Finerenone-associated nephrolithiasis risk compared to spironolactone, SGLT2 inhibitors, and ACEi/ARB: Insights from a large TriNetX cohort study

European Urology 2026

View at publisher

Authors: Z-J. Zhu, Y.H. Chen, C.J. Liu

DOI: 10.1016/s0302-2838(26)01192-9

Cited by: 0

Fields of Study & Subjects

Kidney Stones and Urolithiasis Treatments Chronic Kidney Disease and Diabetes Acute Kidney Injury Research